Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7082217 | 0.85 | MAPT (0.52) | HTR1AHTR7HTTSMN1; SMN2CCR6 | |
| SCHEMBL7079622 | 0.78 | HTR1A (0.55) | KMT2AHTR1AHTR7HTTSMN1; SMN2 | |
| SCHEMBL7081280 | 0.78 | KMT2A (0.44) | KMT2AHTTSMN1; SMN2ADAMTS4NAMPT | |
| SCHEMBL7075758 | 0.77 | PKM (0.63) | KMT2AHTTSMN1; SMN2CCR6POLB | |
| SCHEMBL8881389 | 0.73 | HTT (0.62) | KMT2AHTTSMN1; SMN2POLB | |
| SCHEMBL7079602 | 0.73 | ALDH1A1 (0.64) | KMT2AHTTPOLBHSD17B10LMNA | |
| SCHEMBL10702111 | 0.71 | LMNA (0.56) | KMT2AHTR1AHTR7HTTCCR6 | |
| SCHEMBL12749868 | 0.71 | NAMPT (0.45) | HTTUCHL1USP30ADAMTS4NAMPT | |
| SCHEMBL7080360 | 0.70 | LMNA (0.52) | KMT2AHTR1AHTR7HTTCCR6 | |
| SCHEMBL7109414 | 0.69 | LMNA (0.51) | KMT2AHTR1AHTR7HTTCCR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059265-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158186-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | KMT2A 2747/4885HTR1A 3491/4885HTR7 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.